作者
Yuan‐Yuan Cheng,R Yang,J. Chen,W. Zhang,Chunguang Xie,Qing Hu,Ningning Zhou,Cibo Huang,Sheng Wei,Huaibo Sun,Xiaofei Li,Yan Yu,Jianbo Lai,Hua Yang,H. Fang,Hui Chen,Pengfei Zhang,Kangsheng Gu,Qi Wang,Jingyun Shi,T. Yi,Xiaojiang Xu,X. Ye,Dan Wang,Chunguang Xie,Changxu Liu,Yuan Zheng,Daniel Lin,W. Zhuang,Ping Lu,Guohua Yu,Jun Li,Ying Gu,B. Li,Rong Wu,Ou Jiang,Zhaoguang Wang,Gang Wu,Hao Lin,Diansheng Zhong,Yadong Xu,Yongqian Shu,Donghai Wu,Xiaohong Chen,Sheng Wang,M. Wang
摘要
Small-cell lung cancer (SCLC) is a recalcitrant malignancy. Despite immunochemotherapy showed promise with a 2-month overall survival (OS) benefits in extensive-stage SCLC (ES-SCLC), improving long-term survival remains an unmet need. Limited benefit might attribute to the complicated SCLC microenvironment, which is characterized by immunosuppression, angiogenesis and vascularization. Tumor microenvironment reprogramming and tumor vessel normalization could promote immune cell infiltration, obtaining synergistic effects with immunotherapy.